Comparative Pharmacology
Head-to-head clinical analysis: LEVOLET versus UNITHROID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOLET versus UNITHROID.
LEVOLET vs UNITHROID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levolet (levothyroxine) is a synthetic thyroid hormone that replaces endogenous thyroxine (T4). It is converted to triiodothyronine (T3) in peripheral tissues, which binds to thyroid hormone receptors to regulate gene expression, increasing metabolic rate and protein synthesis.
Synthetic T4 (levothyroxine) is converted to T3, which binds to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate.
Levofloxacin 500 mg orally or intravenously once daily for 5-14 days depending on indication.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 4-6 weeks based on TSH; typical maintenance: 75-150 mcg orally once daily; maximum dose up to 300 mcg daily in severe hypothyroidism.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; shorter in patients with hepatic impairment.
6-7 days for L-thyroxine (T4) in euthyroid patients; prolonged to 9-10 days in hypothyroidism, shortened to 3-4 days in hyperthyroidism. Clinical context: once-daily dosing achieves steady state in 6-8 weeks.
Renal: 70-80% unchanged, biliary/fecal: 20-30% as metabolites.
Renal (approx. 20-40% as unchanged drug and glucuronide conjugates); fecal (minor, via bile).
Category C
Category C
Thyroid Hormone
Thyroid Hormone